Dallas, Texas 01/03/2014 (FINANCIALSTRENDS) – Recently one of the biggest movers in the share market was Athersys, Inc. (NASDAQ:ATHX) that moved about 6.9% from its current value. In fact since December, 2012 the Athersys Inc. has climbed up as high as 22 percent. Everybody is surprised because during last 30 days the company has not witnessed a revision in its estimate but this 6.9% up move is seen as quite encouraging and many analysts are of the view that it needs to be monitored constantly.
The 20 day moving average of Athersys Inc. is $2.27 and the RSI stands at around 84.95. All these are clear cut indications that this stock belongs to little overbought category. The 52 week high of this stock is $1.07 and the 52 week low is $2.98.
Overview of Athersys, Inc. (NASDAQ:ATHX)
Athersys, Inc. (NASDAQ:ATHX) is a clinical stage bi technology company that mainly focuses on the development of its proprietary product called as Multistem. Apart from Multistem the Athersys Inc also deals in the development of therapeutic medicines. It was founded in 1995 and since then this company has been able to create a very diverse pipeline of therapies that are considered as very good for the human life.
If we talk about its ace product called as Multistem, it is actually composed of MAPCs which is also called as multipotent adult progenitor cells. These are the same cells that have been tested in many different clinical and preclinical trials. The main benefit of these cells is that these hold a significant advantage over the stem cells. The origination point of such cells is believed to be adult bone marrow donor. There cells are then stored safely at multiple sites and proves to be quite useful during the treatment of the patient at the later stage of their life.